a Prospective, Multicenter Cohort Study of Ischemic Cerebrovascular Disease

Xiangya Hospital of Central South University1 site in 1 country5,000 target enrollmentNovember 1, 2022

ConditionsIschaemic Stroke

Overview

Phase: N/A
Intervention: Not specified
Conditions: Ischaemic Stroke
Sponsor: Xiangya Hospital of Central South University
Enrollment: 5000
Locations: 1
Primary Endpoint: Cerebrovascular events
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to establish a multicenter, large-scale, prospective cohort of patients with ischemic stroke. Various biological samples such as blood, feces, and urine are collected to identify biomarkers associated with ischemic stroke. By integrating demographic information, clinical indicators, imaging parameters, and biomarker parameters, the study aims to develop risk assessment, early warning, and prognosis prediction models. Additionally, the study aims to identify key genes and explore relevant signaling pathways related to ischemic stroke.

Registry

clinicaltrials.gov

Start Date

November 1, 2022

End Date

November 1, 2027

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Xiangya Hospital of Central South University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Clinical diagnosis of ischemic stroke.
•Age ≥ 18 years.
•Signed informed consent form.

Exclusion Criteria

•Patients with moderate to severe mental disorders or dementia who cannot cooperate to complete the informed consent and follow-up procedures.
•Patients with neurological functional impairment caused by conditions such as migraine aura, epilepsy, or other non-ischemic strokes.
•Agitated patients who cannot cooperate with imaging examinations.
•Pregnant or lactating patients, as well as those planning to become pregnant within 90 days.
•Patients with concurrent malignant tumors or severe systemic diseases with an expected survival period of less than 90 days.
•Patients who have participated in other clinical studies within 30 days prior to enrollment or are currently participating in other interventional clinical studies.